In order to enhance the antitumor activity of CAR-T cells, some researchers also combined decitabine with EGFR-targeting CAR-T cells to conduct anti-bladder tumor studies, and the study found that the combination can enhance the tumor-specific killing of BC (33). Here, EGFR is linked to breast cancer.